A detailed history of Quent Capital, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Quent Capital, LLC holds 226 shares of BIIB stock, worth $39,276. This represents 0.0% of its overall portfolio holdings.

Number of Shares
226
Previous 295 23.39%
Holding current value
$39,276
Previous $68,000 36.76%
% of portfolio
0.0%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

SELL
$189.07 - $236.8 $13,045 - $16,339
-69 Reduced 23.39%
226 $43,000
Q2 2024

Jul 08, 2024

BUY
$190.52 - $236.72 $7,620 - $9,468
40 Added 15.69%
295 $68,000
Q1 2024

May 02, 2024

SELL
$212.02 - $267.71 $17,385 - $21,952
-82 Reduced 24.33%
255 $54,000
Q4 2023

Jun 14, 2024

BUY
$222.59 - $267.94 $10,906 - $13,129
49 Added 17.01%
337 $87,000
Q4 2023

Jan 19, 2024

BUY
$222.59 - $267.94 $10,906 - $13,129
49 Added 17.01%
337 $87,000
Q3 2023

Jun 14, 2024

SELL
$253.3 - $285.89 $1,013 - $1,143
-4 Reduced 1.37%
288 $74,000
Q3 2023

Oct 10, 2023

SELL
$253.3 - $285.89 $1,013 - $1,143
-4 Reduced 1.37%
288 $74,000
Q2 2023

Jun 14, 2024

BUY
$275.25 - $318.06 $1,926 - $2,226
7 Added 2.46%
292 $83,000
Q2 2023

Jul 10, 2023

BUY
$275.25 - $318.06 $1,926 - $2,226
7 Added 2.46%
292 $83,000
Q1 2023

Jun 14, 2024

BUY
$256.56 - $292.34 $7,696 - $8,770
30 Added 11.76%
285 $79,000
Q1 2023

Apr 05, 2023

BUY
$256.56 - $292.34 $1,795 - $2,046
7 Added 2.52%
285 $79,000
Q4 2022

Jan 19, 2023

BUY
$252.44 - $306.72 $5,806 - $7,054
23 Added 9.02%
278 $0
Q3 2022

Nov 10, 2022

BUY
$194.69 - $268.46 $4,867 - $6,711
25 Added 10.87%
255 $68,000
Q2 2022

Aug 08, 2022

BUY
$187.54 - $223.02 $6,563 - $7,805
35 Added 17.95%
230 $47,000
Q1 2022

May 12, 2022

SELL
$193.77 - $244.14 $24,221 - $30,517
-125 Reduced 39.06%
195 $41,000
Q4 2021

Feb 28, 2022

BUY
$223.92 - $287.77 $71,654 - $92,086
320 New
320 $77,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Quent Capital, LLC Portfolio

Follow Quent Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quent Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quent Capital, LLC with notifications on news.